These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 6540581

  • 1. [Hypotensive properties of nisoldipine. Comparative study in essential, renal and renovascular hypertension].
    Wambach G, Breuer G, Kaufmann W.
    Arzneimittelforschung; 1984; 34(5):620-3. PubMed ID: 6540581
    [Abstract] [Full Text] [Related]

  • 2. Effects of nisoldipine on sympathetic activity, the renin-angiotensin-aldosterone system, and water-sodium-calcium metabolism in patients with essential hypertension.
    Iimura O, Kikuchi K, Shimamoto K, Nozawa A, Hasegawa R, Homma C, Komura H, Kobayakawa H.
    Arzneimittelforschung; 1989 Jun; 39(6):710-4. PubMed ID: 2775339
    [Abstract] [Full Text] [Related]

  • 3. The hypotensive effect of nisoldipine in renovascular hypertensive rats.
    Grossman E, Rosenthal T.
    J Hypertens Suppl; 1986 Dec; 4(5):S141-4. PubMed ID: 3471895
    [Abstract] [Full Text] [Related]

  • 4. Hemodynamic effects of nisoldipine in chronic congestive heart failure.
    Vogt A, Kreuzer H.
    Arzneimittelforschung; 1983 Dec; 33(6):877-9. PubMed ID: 6684444
    [Abstract] [Full Text] [Related]

  • 5. Comparison of nisoldipine and atenolol in the treatment of essential hypertension.
    Takahashi H, Fukuyama M, Yoneda S, Okabayashi H, Yoshimura M.
    Arzneimittelforschung; 1989 Mar; 39(3):379-82. PubMed ID: 2667523
    [Abstract] [Full Text] [Related]

  • 6. The control of hypertension and its effect on renal function in rat remnant kidney.
    Eliahou HE, Cohen D, Herzog D, Shechter P, Serban I, Kapuler S, Schiby G, Gavendo S.
    Nephrol Dial Transplant; 1988 Mar; 3(1):38-44. PubMed ID: 3132638
    [Abstract] [Full Text] [Related]

  • 7. Nisoldipine. Central haemodynamics at rest and during exercise in essential hypertension: acute and chronic studies.
    Omvik P, Lund-Johansen P, Haugland H.
    J Hypertens; 1988 Feb; 6(2):95-103. PubMed ID: 3351300
    [Abstract] [Full Text] [Related]

  • 8. [Relationship of the renin-angiotensin-aldosterone system with auricular natriuretic factor in its response to the action of thiazide diuretics and to nifedipine, a sustained-release calcium antagonist].
    Ocón J, Mora-Macià J, Castellet R, del Río G.
    Med Clin (Barc); 1994 Jan 22; 102(2):41-5. PubMed ID: 8133694
    [Abstract] [Full Text] [Related]

  • 9. Rapid development of tolerance to the antihypertensive effect of nisoldipine.
    Ramsay LE, Waller PC.
    J Hum Hypertens; 1988 Mar 22; 1(4):277-80. PubMed ID: 3065506
    [Abstract] [Full Text] [Related]

  • 10. Comparative acute effects of the calcium channel blockers tiapamil, nisoldipine, and nifedipine on blood pressure and some regulatory factors in normal and hypertensive subjects.
    Laederach K, Weidmann P, Lauener F, Gerber A, Ziegler WH.
    J Cardiovasc Pharmacol; 1986 Mar 22; 8(2):294-302. PubMed ID: 2422467
    [Abstract] [Full Text] [Related]

  • 11. Nisoldipine (BAY K 5552), a new calcium antagonist. Antihypertensive effect in conscious, unrestrained renal hypertensive dogs.
    Knorr A.
    Arch Int Pharmacodyn Ther; 1982 Nov 22; 260(1):141-50. PubMed ID: 7165419
    [Abstract] [Full Text] [Related]

  • 12. Acute hypotensive, hemodynamic effects of long-term treatment with niludipine, a Ca2+-antagonist, in patients with essential hypertension. Niludipine monotherapy and combination with a beta-blocker and a diuretic).
    Aoki K, Sato K.
    Arzneimittelforschung; 1982 Nov 22; 32(9):1141-5. PubMed ID: 6756418
    [Abstract] [Full Text] [Related]

  • 13. Verapamil compared with nifedipine in the treatment of essential hypertension.
    Midtbø K, Hals O, van der Meer J.
    J Cardiovasc Pharmacol; 1982 Nov 22; 4 Suppl 3():S363-8. PubMed ID: 6184569
    [Abstract] [Full Text] [Related]

  • 14. Acute and chronic hypotensive effects of nifedipine and niludipine in hypertensive patients with chronic renal failure.
    Kusano E, Asano Y, Takeda K, Terao N, Hosoda S.
    Arzneimittelforschung; 1984 Nov 22; 34(5):624-9. PubMed ID: 6432001
    [Abstract] [Full Text] [Related]

  • 15. Central hemodynamic effects at rest and during exercise of acute and chronic treatment with nisoldipine in essential hypertension.
    Omvik P, Lund-Johansen P, Haugland H.
    J Cardiovasc Pharmacol; 1987 Nov 22; 10 Suppl 10():S182-4. PubMed ID: 2455128
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics and hemodynamic effects of long-term nisoldipine treatment in hypertensive patients.
    van Harten J, van Brummelen P, Danhof M, Quekel RP, Breimer DD.
    J Cardiovasc Pharmacol; 1989 Apr 22; 13(4):624-9. PubMed ID: 2471001
    [Abstract] [Full Text] [Related]

  • 17. Pharmacological studies on a new dihydrothienopyridine calcium antagonist. 3rd communication: antihypertensive effects of S-(+)-methyl-4,7-dihydro-3-isobutyl-6-methyl-4-(3-nitrophenyl)thieno[2, 3-b] pyridine-5-carboxylate in hypertensive rats and dogs.
    Ueda M, Matsumura S, Masui M, Matsuura E, Kawakami M, Fujitomo H, Umeda T, Kagawa H, Hirohata S, Shima K.
    Arzneimittelforschung; 1993 Dec 22; 43(12):1282-90. PubMed ID: 8141815
    [Abstract] [Full Text] [Related]

  • 18. Hemodynamic effects of the new vasodilator drug Bay k 5552 in man.
    Vogt A, Neuhaus KL, Kreuzer H.
    Arzneimittelforschung; 1980 Dec 22; 30(12):2162-4. PubMed ID: 7194078
    [Abstract] [Full Text] [Related]

  • 19. Treatment of mild-to-moderate hypertension with calcium channel blockers: a multicentre comparison of once-daily nifedipine GITS with once-daily amlodipine.
    Kes S, Caglar N, Canberk A, Deger N, Demirtas M, Dortlemez H, Kiliccioglu B, Kozan O, Ovunc K, Turkoglu C.
    Curr Med Res Opin; 2003 Dec 22; 19(3):226-37. PubMed ID: 12803737
    [Abstract] [Full Text] [Related]

  • 20. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.
    Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, Kitajima T, Ideura T, Koyama A, Sugisaki T, Suzuki H, Umemura S, Kawaguchi Y, Uchida S, Kuwahara M, Yamazaki T, Japanese Lasartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study Investigators.
    Clin Exp Nephrol; 2003 Sep 22; 7(3):221-30. PubMed ID: 14586719
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.